TY - JOUR
T1 - Brief report
T2 - How many patients complete an adequate trial of donepezil?
AU - Roe, Catherine M.
AU - Anderson, Michael J.
AU - Spivack, Barney
PY - 2002
Y1 - 2002
N2 - Pharmacy claims data were used to evaluate medication adherence among 59 new users of donepezil aged 65 to 94 years. The probability (± 95% confidence interval) of a new user continuing donepezil at 90 days was .797 ± .103 and at 180 days was .627 ± .124. Additionally, 13.9% of those who continued therapy for at least 180 days showed gaps in treatment of six weeks or more. These results suggest that adherence with donepezil could be improved in clinical practice.
AB - Pharmacy claims data were used to evaluate medication adherence among 59 new users of donepezil aged 65 to 94 years. The probability (± 95% confidence interval) of a new user continuing donepezil at 90 days was .797 ± .103 and at 180 days was .627 ± .124. Additionally, 13.9% of those who continued therapy for at least 180 days showed gaps in treatment of six weeks or more. These results suggest that adherence with donepezil could be improved in clinical practice.
KW - Cognitive disorders/dementia
KW - Donepezil
KW - Medication adherence
UR - http://www.scopus.com/inward/record.url?scp=0036216282&partnerID=8YFLogxK
U2 - 10.1097/00002093-200201000-00008
DO - 10.1097/00002093-200201000-00008
M3 - Article
C2 - 11882749
AN - SCOPUS:0036216282
SN - 0893-0341
VL - 16
SP - 49
EP - 51
JO - Alzheimer disease and associated disorders
JF - Alzheimer disease and associated disorders
IS - 1
ER -